The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C. L. M., Schinkel, A. H., van de Vijver, M. J., Scheper, R. J., & Schellens, J. H. M. (2001) · PubMed · Cited by 1,130
Bile salt transporters: molecular characterization, function, and regulation
Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00027.2002 · Cited by 999
Statins and the Risk of Colorectal Cancer
Poynter, J. N., Gruber, S. B., Higgins, P. D. R., Almog, R., Bonner, J. D., Rennert, H. S., Low, M., Greenson, J. K., & Rennert, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043792 · Cited by 816
Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
Levine, G. N., Keaney, J. F., & Vita, J. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320807 · Cited by 672
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
Hsiang, B., Zhu, Y., Wang, Z., Wu, Y., Sasseville, V., Yang, W.-P., & Kirchgessner, T. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37161 · Cited by 641
Tirona, R. G., Leake, B. F., Merino, G., & Kim, R. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103792200 · Cited by 626
Self-citationMeier, P. J., & Stieger, B. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.082201.100300 · Cited by 586
The evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 574
Nishizato, Y. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00060-2 · Cited by 511
Niemi, M., Schaeffeler, E., Lang, T., Fromm, M. F., Neuvonen, M., Kyrklund, C., Backman, J. T., Kerb, R., Schwab, M., Neuvonen, P. J., et al. (2004) · Pharmacogenetics · doi:10.1097/01.fpc.0000114750.08559.32 · Cited by 418
McTaggart, F., Buckett, L., Davidson, R., Holdgate, G., McCormick, A., Schneck, D., Smith, G., & Warwick, M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01454-0 · Cited by 413
The response‐to‐retention hypothesis of atherogenesis reinforced
Williams, K. J., & Tabas, I. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199810000-00012 · Cited by 395
Shitara, Y., Itoh, T., Sato, H., Li, A. P., & Sugiyama, Y. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041921 · Cited by 340
SIMONSON, S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.03.010 · Cited by 330
Tirona, R. G., Leake, B. F., Wolkoff, A. W., & Kim, R. B. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043026 · Cited by 324
Self-citationNozawa, T., Nakajima, M., Tamai, I., Noda, K., Nezu, J.-I., Sai, Y., Tsuji, A., & Yokoi, T. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.302.2.804 · Cited by 318
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
Mwinyi, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.016 · Cited by 293
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin
Schneck, D. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.12.014 · Cited by 292
The sodium bile salt cotransport family SLC10
Hagenbuch, B., & Dawson, P. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1130-z · Cited by 266
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H., & Sugiyama, Y. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014019 · Cited by 256
Organic anion‐transporting polypeptide (OATP) transporter family and drug disposition
Kim, R. B. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.5.x · Cited by 200
Self-citationHo, R. H., Leake, B. F., Roberts, R. L., Lee, W., & Kim, R. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305782200 · Cited by 199
Self-citationAbsolute oral bioavailability of rosuvastatin in healthy white adult male volunteers
Martin, P. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80316-8 · Cited by 191
Organic Anion Transporting Polypeptide Mediates Organic Anion/HCO3− Exchange
Satlin, L. M., Amin, V., & Wolkoff, A. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26340 · Cited by 180
Comparative pharmacology of rosuvastatin
McTaggart, F. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)00004-7 · Cited by 147
Tachibana-Iimori, R., Tabara, Y., Kusuhara, H., Kohara, K., Kawamoto, R., Nakura, J., Tokunaga, K., Kondo, I., Sugiyama, Y., & Miki, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.375 · Cited by 144
Paulusma, C. C., Kothe, M., Bakker, C., Bosma, P. J., van Bokhoven, I., van Marle, J., Bolder, U., Tytgat, G. N. J., & Elferink, R. P. J. O. (2000) · Hepatology · doi:10.1002/hep.510310319 · Cited by 144
Temporal Gene Expression Analysis of Monolayer Cultured Rat Hepatocytes
Baker, T. K., Carfagna, M. A., Gao, H. T., Dow, E. R., Li, Q. S., Searfoss, G. H., & Ryan, T. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx015518a · Cited by 143
Shitara, Y., Li, A. P., Kato, Y., Lu, C., Ito, K., Itoh, T., & Sugiyama, Y. (2003) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.18.33 · Cited by 116
Regazzi, M. B., Iacona, I., Campana, C., Raddato, V., Lesi, C., Perani, G., Gavazzi, A., & Viganò, M. (1993) · PubMed · Cited by 114
Comparative effects of lipid-lowering therapies
Davidson, M. H., & Toth, P. P. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.007 · Cited by 107
FUNCTIONAL EXPRESSION OF SINUSOIDAL DRUG TRANSPORTERS IN PRIMARY HUMAN AND RAT HEPATOCYTES
Jigorel, É., Vée, M. L., Boursier-Neyret, C., Bertrand, M., & Fardel, O. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004762 · Cited by 107
Singer, I. I., Kawka, D. W., Kazazis, D. M., Alberts, A. W., Chen, J. S., Huff, J. W., & Ness, G. C. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.17.5556 · Cited by 102
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects
Cooper, K. J., Martin, P. D., Dane, A. L., Warwick, M. J., Raza, A., & Schneck, D. W. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01720.x · Cited by 89
Efficacy and safety of rosuvastatin in treatment of dyslipidemia
McKenney, J. M. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.10.1033 · Cited by 86
Kouzuki, H., Suzuki, H., Ito, K., Ohashi, R., & Sugiyama, Y. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37686-4 · Cited by 78
OATP-C(OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients
Morimoto, K., Ueda, S., Seki, N., IGAWA, Y., KAMEYAMA, Y., Shimizu, A., Oishi, T., Hosokawa, M., Iesato, K., & Mori, S. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.11.081 · Cited by 25
Pleiotropic effects of statins: Moving beyond cholesterol control
Garcia, P. J. (2005) · Current Atherosclerosis Reports · doi:10.1007/s11883-005-0073-6 · Cited by 20
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Roth, M., Obaidat, A., & Hagenbuch, B. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01724.x · Cited by 767
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
What do drug transporters really do?
Nigam, S. K. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4461 · Cited by 527
Metadata
- Authors
- Ho, R. H., Tirona, R. G., Leake, B. F., Glaeser, H., Lee, W., Lemke, C. J., Wang, Y., & Kim, R. B.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 130
- Issue
- 6
- Pages
- 1793-1806
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1964471078
- Cited by
- 611
- References
- 39
- FWCI
- 14.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.